Decoding Pfizer Inc.'s Strong Earnings and Game-Changing Pipeline

On Tuesday's edition of Market Checkup, Motley Fool health-care analyst David Williamson lookw at the biggest winners and losers in health-care stocks today.

Shares of Pfizer were up 3% today, an impressive single-day move for a $200 billion company, after it reported strong earnings results. The company beat on earnings-per-share estimates, and delivered 2014 guidance above expectations on the high end, though the midpoint was a little lower than analysts had hoped. Pfizer also now boasts three different drugs each delivering at least $1 billion in quarterly sales: Lyrica, Prevnar, and Enbrel.

In this segment, David looks through the ups and downs of the company's pipeline at the moment and tells investors why this is definitely a stock to keep an eye on in the coming months.

So what's the best way for investors to play the biotech space today?
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In The Motley Fool's brand-new free report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that Big Pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

The article Decoding Pfizer Inc.'s Strong Earnings and Game-Changing Pipeline originally appeared on

David Williamson owns shares of Pfizer. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story